Agenus Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Agenus şirketinin kazançları yıllık ortalama -14.5% oranında azalırken, Biotechs sektörünün kazançları yıllık 19.1% oranında artan oldu. Gelirler yıllık ortalama 4.6% oranında artan oldu.

Anahtar bilgiler

-14.5%

Kazanç büyüme oranı

12.6%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	4.6%
Özkaynak getirisi	n/a
Net Marj	-142.0%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Agenus: Novel Drugs That Just Are Not Novel

Jul 24

There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise

May 21

Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results

May 09

Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

Mar 29

Agenus: 2024 May Finally Be The Year For A Major Turnaround

Jan 18

Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet

Dec 22

News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts

Nov 09

A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)

Oct 04

Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts

May 10

Agenus Inc.'s Imminent 1181/Bal Data Release And MiNK IPO Should Lead To Enormous Valuation Gains

Aug 25

Agenus Multiple Value-Adding Events Ahead

Aug 18

Party Time: Brokers Just Made Major Increases To Their Agenus Inc. (NASDAQ:AGEN) Earnings Forecasts

Aug 11

Gelir ve Gider Dağılımı

Agenus nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqCM:AGEN Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Sep 24	160	-228	72
30 Jun 24	160	-224	74
31 Mar 24	161	-240	77
31 Dec 23	156	-246	79
30 Sep 23	101	-271	83
30 Jun 23	99	-263	82
31 Mar 23	95	-240	80
31 Dec 22	98	-220	81
30 Sep 22	90	-215	78
30 Jun 22	320	18	81
31 Mar 22	310	-19	79
31 Dec 21	296	-24	76
30 Sep 21	307	4	74
30 Jun 21	69	-226	67
31 Mar 21	85	-190	65
31 Dec 20	88	-181	59
30 Sep 20	91	-174	52
30 Jun 20	97	-168	49
31 Mar 20	85	-171	46
31 Dec 19	150	-108	46
30 Sep 19	122	-126	43
30 Jun 19	115	-113	41
31 Mar 19	115	-87	39
31 Dec 18	37	-160	37
30 Sep 18	39	-147	37
30 Jun 18	29	-151	36
31 Mar 18	18	-158	35
31 Dec 17	43	-121	34
30 Sep 17	40	-112	33
30 Jun 17	41	-116	33
31 Mar 17	44	-113	32
31 Dec 16	23	-127	33
30 Sep 16	25	-117	33
30 Jun 16	27	-89	31
31 Mar 16	27	-101	32
31 Dec 15	25	-88	28
30 Sep 15	19	-98	25
30 Jun 15	14	-93	23
31 Mar 15	10	-61	22
31 Dec 14	7	-43	21
30 Sep 14	6	-22	20
30 Jun 14	5	-22	18
31 Mar 14	3	-25	17
31 Dec 13	3	-33	14

Kaliteli Kazançlar: AGEN şu anda kârlı değil.

Büyüyen Kar Marjı: AGEN şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: AGEN kârlı değildir ve zararlar son 5 yılda yılda 14.5% oranında artmıştır.

Büyüme Hızlandırma: AGEN 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: AGEN kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 16.6% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: AGEN 'un yükümlülükleri varlıklarından fazla olduğundan Özsermaye Getirisi'ni hesaplamak zordur.

Agenus Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Agenus Inc. to Report Q3, 2024 Results on Nov 12, 2024

Agenus Inc. to Report Q2, 2024 Results on Aug 08, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Agenus Inc. to Report Q1, 2024 Results on May 07, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Agenus Inc. to Report Q4, 2023 Results on Mar 14, 2024

Recent updates

Agenus Inc. to Report Q3, 2024 Results on Nov 12, 2024

Rosen Law Firm Announces the Filing of a Class Action Lawsuit Against Agenus Inc

Agenus Inc. Appoints Tom Harrison to Its Board of Directors

Agenus Inc. to Report Q2, 2024 Results on Aug 08, 2024

Agenus: Novel Drugs That Just Are Not Novel

Agenus Inc. Announces End-Of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for Bot/Bal in MSS Colorectal Cancer

Agenus Inc Announces Results from an Investigator-Sponsored Trial (IST) of Botensilimab and Balstilimab (BOT/BALl) in the Neoadjuvant Setting for Colon Cancer

Agenus Inc. Announces Availability of Botensilimab for Clinical Studies

Agenus Appoints Jennifer Buell to Its Board of Directors

There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise

Agenus Inc. announces FDA Grants Agenus Type B End-Of-Phase 2 Meeting to Discuss Bot/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer

Consensus revenue estimates fall by 27%

New major risk - Financial position

Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results

Ligand and Agenus Enter into $100 Million Royalty Financing Agreement to Support Agenus’ Key Development Initiatives in the Ongoing Bot/Bal Clinical Development Program

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement

Agenus Inc., Annual General Meeting, Jun 11, 2024

Agenus Inc. to Report Q1, 2024 Results on May 07, 2024

New major risk - Share price stability

Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer

Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

Consensus revenue estimates increase by 30%, EPS downgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Agenus Inc. Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024

Agenus Inc. to Report Q4, 2023 Results on Mar 14, 2024

Founder recently bought US$324k worth of stock

Agenus: 2024 May Finally Be The Year For A Major Turnaround

Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet

Agenus Inc. Announces Data from an Investigator Sponsored Trial Evaluating Botensilimab in Combination with Balstilimab in Neoadjuvant Colorectal Cancer

Agenus Receives Notice from Nasdaq Stock Market's Listing Qualifications Department

Agenus Receives Notice from Nasdaq Stock Market's Listing Qualifications Department

News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 17% to US$6.67

Agenus Inc. to Report Q3, 2023 Results on Nov 07, 2023

Agenus Inc. Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma

Agenus Inc. Announces Expanded Data from the Company's Phase 1B Study of Botensilimab in Combination with Balstilimab (Bal, Anti-Pd-1) in Patients with Advanced Sarcomas

Now 22% undervalued after recent price drop

Agenus Inc. Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer

A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)

Agenus Inc. Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers

Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Agenus Inc. to Report Q2, 2023 Results on Aug 08, 2023

Agenus' Botensilimab/Balstilimab Combination Achieves Unprecedented Survival in Advanced Colorectal Cancer

Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Agenus Inc. Announces the Resignation of Wadih Jordan as Director, Effective December 31, 2022

Price target decreased to US$6.33

Insufficient new directors

Agenus Inc. Data At SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Agenus Inc. to Report Q3, 2022 Results on Nov 08, 2022

Agenus Inc. Announces GSK Disclose Positive Pivotal Phase III Trial Results for Its Respiratory Syncytial Virus Vaccine Candidate

VBI Vaccines, Agenus to examine VBI-1901 + balstilimab combo for glioblastoma

Investor sentiment improved over the past week

Price target decreased to US$6.33

Agenus New Trials Set It Up For The Long Haul

Investor sentiment deteriorated over the past week

Agenus: It's Always Tomorrow

Agenus Initiates Botensilimab Phase 2 Activate Trials in Advanced MSS Colorectal Cancer and Advanced Melanoma

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Agenus GAAP EPS of -$0.17, revenue of $20.93M

Agenus Inc. Announces First Patient Dosed in Phase 1 Study of AGEN1571 (Anti-ILT2) in Advanced Solid Tumors

Agenus Inc. to Report Q2, 2022 Results on Aug 09, 2022

Agenus: Successfully Pulled Itself Away From Disaster